Search for a trial

A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA

This study will evaluate how safe administering obinutuzumab as a short duration infusion (SDI) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in patients with previously untreated advanced FL is.

Test-retest repeatability of quantitative radiomics features of FDG PET/CT studies in patients with diffuse large B cell lymphoma

At the moment it is unknown which radiomics features are robust against variations in image characteristics. The objective of this study is to check the robustness of radiomics features, and to investigate wheter specific pre- and postprocessing…

Cardiotoxicity and other Late effects After Radiotherapy and ImmunochemoTherapy in Non-Hodgkin lYmphoma

Objective: Our main objective is to assess in detail risk factors for cardiovascular disease and cardiotoxicity and to compare heart function parameters, vascular parameters and biomarkers associated with cardiovascular function among 5- to 18-year…

A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)

Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…